$TNON
Tenon Medical, Inc. Stock $tnon

$tnon Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000121390023087015 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2023 Q2
Revenue	$808.0K	$944.0K	$743.0K
YoY Change	191.7%	353.85%	450.37%
Cost Of Revenue	$249.0K	$409.0K	$549.0K
YoY Change	-48.55%	35.43%	102.58%
Gross Profit	$559.0K	$535.0K	$194.0K
YoY Change	-370.05%	-669.15%	-242.65%
Gross Profit Margin	69.18%	56.67%	26.11%
Selling, General & Admin	$3.009M	$3.176M	$3.615M
YoY Change	-56.45%	33.95%	-22.47%
% of Gross Profit	538.28%	593.64%	1863.4%
Research & Development	$691.0K	$737.0K	$901.0K
YoY Change	-14.9%	-7.53%	37.14%
% of Gross Profit	123.61%	137.76%	464.43%
Depreciation & Amortization	$93.00K	$46.00K	$35.00K
YoY Change	272.0%	91.67%	84.21%
% of Gross Profit	16.64%	8.6%	18.04%
Operating Expenses	$3.700M	$3.913M	$4.516M
YoY Change	-52.08%	23.52%	-15.11%
Operating Profit	-$3.141M	-$3.378M	-$4.322M
YoY Change	-60.38%	3.56%	-20.78%
Interest Expense	$7.000K	$4.000K
YoY Change	-91.25%	-94.44%
% of Operating Profit
Other Income/Expense, Net	$0.00	$46.00K	$37.00K
YoY Change	-100.0%	-49.45%	-215.63%
Pretax Income	-$3.134M	-$3.332M	-$4.285M
YoY Change	-60.35%	5.08%	-21.92%
Income Tax
% Of Pretax Income
Net Earnings	-$3.134M	-$3.332M	-$4.285M
YoY Change	-60.35%	5.08%	-21.92%
Net Earnings / Revenue	-387.87%	-352.97%	-576.72%
Basic Earnings Per Share		-$1.46	-$0.33
Diluted Earnings Per Share	-$1.24	-$1.46	-$0.33
COMMON SHARES
Basic Shares Outstanding	2.471M shares	22.61M shares	11.25M
Diluted Shares Outstanding		2.276K shares	13.05K shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.428M	$3.371M	$6.345M
YoY Change	-71.67%	-73.11%	-60.38%
Cash & Equivalents	$2.428M	$3.371M	$5.852M
Short-Term Investments	$0.00	$0.00	$493.0K
Other Short-Term Assets	$389.0K	$345.0K	$413.0K
YoY Change	190.3%	94.92%	197.12%
Inventory	$554.0K	$474.0K	$570.0K
Prepaid Expenses	$389.0K	$345.0K	$413.0K
Receivables	$518.0K	$773.0K	$601.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$3.889M	$4.963M	$7.929M
YoY Change	-58.39%	-63.68%	-52.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.607M	$956.0K	$945.0K
YoY Change	102.65%	225.17%	292.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$2.500M
YoY Change
Other Assets	$849.0K	$695.0K	$219.0K
YoY Change	1017.11%	1262.75%	329.41%
Total Long-Term Assets	$2.456M	$2.355M	$1.926M
YoY Change	40.99%	85.14%	51.3%
TOTAL ASSETS
Total Short-Term Assets	$3.889M	$4.963M	$7.929M
Total Long-Term Assets	$2.456M	$2.355M	$1.926M
Total Assets	$6.345M	$7.318M	$9.855M
YoY Change	-42.78%	-51.01%	-45.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$433.0K	$763.0K	$912.0K
YoY Change	-21.27%	80.81%	164.35%
Accrued Expenses	$1.534M	$571.0K	$1.130M
YoY Change	113.95%	-5.31%	-31.8%
Deferred Revenue
YoY Change
Short-Term Debt	$1.173M	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.140M	$3.085M	$6.866M
YoY Change	24.11%	143.68%	207.07%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.427M	$1.716M	$2.086M
YoY Change	5.2%	137.02%	166.75%
Total Long-Term Liabilities	$2.427M	$1.716M	$2.086M
YoY Change	5.2%	137.02%	166.75%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.140M	$3.085M	$6.866M
Total Long-Term Liabilities	$2.427M	$1.716M	$2.086M
Total Liabilities	$5.567M	$4.801M	$8.952M
YoY Change	15.09%	141.26%	196.62%
SHAREHOLDERS EQUITY
Retained Earnings	-$55.07M	-$51.94M	-$48.61M
YoY Change	39.45%	64.43%	71.06%
Common Stock	$55.90M	$2.000K	$22.00K
YoY Change	508054.55%	-81.82%	100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$778.0K	$2.517M	$903.0K
YoY Change
Total Liabilities & Shareholders Equity	$6.345M	$7.318M	$9.855M
YoY Change	-42.78%	-51.01%	-45.65%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$3.134M	-$3.332M	-$4.285M
YoY Change	-60.35%	5.08%	-21.92%
Depreciation, Depletion And Amortization	$93.00K	$46.00K	$35.00K
YoY Change	272.0%	91.67%	84.21%
Cash From Operating Activities	-$2.278M	-$3.155M	-$3.176M
YoY Change	-32.7%	-7.56%	14.95%
INVESTING ACTIVITIES
Capital Expenditures	$92.00K	$59.00K	$128.0K
YoY Change	-84.69%	-176.62%	-412.2%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$493.0K	$1.257M
YoY Change	-100.0%	-139.76%	-115.44%
Cash From Investing Activities	-$92.00K	$434.0K	$1.129M
YoY Change	-103.93%	-132.95%	-113.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.371M	261.0K	4.707M
YoY Change	-5584.0%		-66.84%
NET CHANGE
Cash From Operating Activities	-2.278M	-3.155M	-3.176M
Cash From Investing Activities	-92.00K	434.0K	1.129M
Cash From Financing Activities	1.371M	261.0K	4.707M
Net Change In Cash	-999.0K	-2.460M	2.660M
YoY Change	-6.72%	-47.99%	-18.1%
FREE CASH FLOW
Cash From Operating Activities	-$2.278M	-$3.155M	-$3.176M
Capital Expenditures	$92.00K	$59.00K	$128.0K
Free Cash Flow	-$2.370M	-$3.214M	-$3.304M
YoY Change	-40.54%	-3.66%	21.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	us-gaap	Interest Expense InterestExpense		usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.91
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1573	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2276	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	692	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41364
	dei	Entity Registrant Name EntityRegistrantName	TENON MEDICAL, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-5574718
	dei	Entity Address Address Line1 EntityAddressAddressLine1	104 Cooper Court
	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Gatos
	dei	Entity Address Country EntityAddressCountry	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	95032
	dei	City Area Code CityAreaCode	(408)
	dei	Local Phone Number LocalPhoneNumber	649-5760
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2471046	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3371000	usd
	tnon	Long Term Volatility Percentage LongTermVolatilityPercentage	0.60	pure
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2129000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	6441000	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	773000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	228000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	474000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	415000	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	345000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	134000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	4963000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	9347000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	956000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	793000	usd
CY2023Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	51000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	51000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	704000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	873000	usd
CY2023Q3	us-gaap	Deferred Costs DeferredCosts	644000	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts	25000	usd
CY2023Q3	us-gaap	Assets Assets	7318000	usd
CY2022Q4	us-gaap	Assets Assets	11089000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	763000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	550000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	571000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	717000	usd
CY2023Q3	tnon	Accrued Commissions Current AccruedCommissionsCurrent	1502000	usd
CY2022Q4	tnon	Accrued Commissions Current AccruedCommissionsCurrent	1035000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	249000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	228000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3085000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2530000	usd
CY2023Q3	tnon	Accrued Commissions Noncurrent AccruedCommissionsNoncurrent	1222000	usd
CY2022Q4	tnon	Accrued Commissions Noncurrent AccruedCommissionsNoncurrent	1624000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	494000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	683000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	4801000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	4837000	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2471014	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2471014	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1123680	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1123680	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	54556000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	45843000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-51939000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39492000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-102000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-100000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	2517000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	6252000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7318000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11089000	usd
CY2023Q3	us-gaap	Revenues Revenues	944000	usd
CY2022Q3	us-gaap	Revenues Revenues	208000	usd
	us-gaap	Revenues Revenues	2120000	usd
	us-gaap	Revenues Revenues	414000	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	409000	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	302000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	1438000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	848000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	535000	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	-94000	usd
	us-gaap	Gross Profit GrossProfit	682000	usd
	us-gaap	Gross Profit GrossProfit	-434000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	737000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	797000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2472000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2016000	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1527000	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	645000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5436000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2864000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1649000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1726000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5360000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5483000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	3913000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	3168000	usd
	us-gaap	Operating Expenses OperatingExpenses	13268000	usd
	us-gaap	Operating Expenses OperatingExpenses	10363000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3378000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3262000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12586000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10797000	usd
CY2023Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	50000	usd
CY2022Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	72000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	143000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	108000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	4000	usd
	us-gaap	Interest Expense InterestExpense	4000	usd
	us-gaap	Interest Expense InterestExpense	362000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	19000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	39000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	46000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	91000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	139000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-215000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-3332000	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-3171000	usd
	us-gaap	Profit Loss ProfitLoss	-12447000	usd
	us-gaap	Profit Loss ProfitLoss	-11012000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.46
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.82
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.91
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-15.91
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2276	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1124	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1573	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	692	shares
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-3332000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3171000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12447000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11012000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-10000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	16000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-37000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-30000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-19000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-18000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-40000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-3362000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-3200000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-12449000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-11089000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	903000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1070000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	453000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	289000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	3164000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-30000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-3332000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	2517000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	15113000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1034000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-29000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3171000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	12947000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	6252000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3164000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	1643000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	3164000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	453000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	289000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12447000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	2517000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-20552000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1755000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	13765000	usd
	tnon	Stock Issued During Period Value Exchange Of Share StockIssuedDuringPeriodValueExchangeOfShare	12367000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	1272000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	13868000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1561000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-77000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11012000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	12947000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12447000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11012000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	37000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	362000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3164000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1755000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1561000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	106000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	53000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	169000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	157000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	545000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	68000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	59000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	622000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	257000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	100000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	213000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-56000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-81000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-485000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-168000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-148000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9905000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8640000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	6996000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	4404000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	493000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	9381000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	269000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	246000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6234000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5223000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4808000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14139000	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	453000	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	330000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4931000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14139000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-18000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-40000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1242000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	236000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2129000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2917000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3371000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3153000	usd
	tnon	Common Stock Issued Upon Conversion Of Preferred Stock CommonStockIssuedUponConversionOfPreferredStock	13639000	usd
	tnon	Common Stock Issued Upon Conversion Of Debt CommonStockIssuedUponConversionOfDebt	13868000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	743000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	218000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	212000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P2Y9M
CY2023Q3	us-gaap	Share Price SharePrice	1
	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	1
CY2023Q2	us-gaap	Equity Method Investments EquityMethodInvestments	2500000	usd
CY2023Q2	us-gaap	Partners Capital Account Units Sold In Public Offering PartnersCapitalAccountUnitsSoldInPublicOffering	1000000	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1	shares
CY2023Q2	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	4866000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Use of estimates</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, realization of deferred tax assets, accrued liabilities, accrued commissions, incremental borrowing rate, obsolescence of inventory, stock-based compensation and the fair value of investments, inventory and of the Company’s common stock.</p>
CY2022Q2	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	1	shares
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	effected a 1-for-10 reverse stock split (the “2023 Reverse Stock Split”) by filing an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Delaware Secretary of State. The 2023 Reverse Stock Split combined every ten shares of our common stock issued and outstanding immediately prior to effecting the 2023 Reverse Stock Split into one share of common stock. No fractional shares were issued in connection with the 2023 Reverse Stock Split. All historical share and per share amounts reflected throughout this document have been adjusted to reflect the 2022 Reverse Stock Split and the 2023 Reverse Stock Split.
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
	tnon	Percentage Of Valuation Allowance In Deferred Tax Assets PercentageOfValuationAllowanceInDeferredTaxAssets	1	pure
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2204841	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	228087	shares
CY2022Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	72000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	108000	usd
CY2022Q3	tnon	Accrued Interest AccruedInterest	0	usd
CY2022Q4	tnon	Accrued Interest AccruedInterest	13000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1142000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	873000	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	186000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	80000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	956000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	793000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	46000	usd
CY2022Q3	us-gaap	Depreciation Depreciation	24000	usd
	us-gaap	Depreciation Depreciation	106000	usd
	us-gaap	Depreciation Depreciation	53000	usd
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	8574	shares
CY2023Q3	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	306000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	452000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	265000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	265000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	571000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	717000	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	73000	usd
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	73000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	219000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	219000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	704000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	873000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	249000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	228000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	494000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	683000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	743000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	911000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	75000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	301000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	310000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	144000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	830000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	87000	usd
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1000000	shares
CY2023Q2	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	4808000	usd
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.6
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P5Y
CY2023Q2	tnon	Offering Warrant Exercise Price OfferingWarrantExercisePrice	3.146
CY2023Q2	tnon	Aggregate Gross Sales Price AggregateGrossSalesPrice	5500000	usd
CY2023Q2	tnon	Percentage Of Gross Proceeds PercentageOfGrossProceeds	0.03	pure
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	204604	shares
CY2023Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	204604	shares
	tnon	Purchase Agreement PurchaseAgreement	10000000	usd
	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	10000	shares
	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	(i) up to 12,500 shares of common stock, if the closing sale price of its common stock on Nasdaq on such business day is at least $15.00 per share and (ii) up to 15,000 shares of common stock, if the closing sale price of its common stock on Nasdaq on such business day is at least $25.00 per share
	tnon	Purchase Exceed Amount PurchaseExceedAmount	500000	usd
	tnon	Number Of Shares NumberOfShares	100000	shares
	tnon	Percentage Of Outstanding Shares PercentageOfOutstandingShares	0.0499	pure
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one vote
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1070000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1034000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3164000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	721000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	0	usd
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2000000	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.6
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P5Y
	tnon	Class Of Warrants Of Rights Grant Date Fair Value Of Warrants ClassOfWarrantsOfRightsGrantDateFairValueOfWarrants	3164
	tnon	Fair Value Of Offering Warrant FairValueOfOfferingWarrant	1.58
CY2023Q3	us-gaap	Net Asset Value Per Share NetAssetValuePerShare	3
	tnon	Daily Return Rate DailyReturnRate	0.0518	pure
	tnon	Annual Volatility AnnualVolatility	1	pure
	tnon	Deviation Deviation	0.063	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0399	pure
	tnon	Disclosure Of Reconciliation Of Liability DisclosureOfReconciliationOfLiability	A reconciliation of the liability under clause (b) and clause (c) for the nine months ended September 30, 2023 is as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Balance at December 31, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,560</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Amounts paid during 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(406</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Accretion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">381</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 10pt; padding-bottom: 4pt">Balance at September 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,535</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>
CY2022Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	2560000	usd
	us-gaap	Loss Contingency Accrual Payments LossContingencyAccrualPayments	406000	usd
	us-gaap	Accretion Expense AccretionExpense	381000	usd
CY2023Q3	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	2535000	usd
CY2023Q3	tnon	Additional Compensation Per Quarter AdditionalCompensationPerQuarter	62.5
CY2023Q3	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	10	shares
CY2023Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax		usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments		usd
	us-gaap	Paid In Kind Interest PaidInKindInterest		usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
	tnon	Common Stock Issued Upon Conversion Of Preferred Stock CommonStockIssuedUponConversionOfPreferredStock		usd
	tnon	Common Stock Issued Upon Conversion Of Debt CommonStockIssuedUponConversionOfDebt		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001560293

Files In Submission

Name	View Source	Status
0001213900-23-087015-index-headers.html	Edgar Link	pending
0001213900-23-087015-index.html	Edgar Link	pending
0001213900-23-087015.txt	Edgar Link	pending
0001213900-23-087015-xbrl.zip	Edgar Link	pending
f10q0923ex31-1_tenonmed.htm	Edgar Link	pending
f10q0923ex31-2_tenonmed.htm	Edgar Link	pending
f10q0923ex32-1_tenonmed.htm	Edgar Link	pending
f10q0923ex32-2_tenonmed.htm	Edgar Link	pending
f10q0923_tenonmed.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
f10q0923_tenonmed_htm.xml	Edgar Link	completed
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tnon-20230930.xsd	Edgar Link	pending
tnon-20230930_cal.xml	Edgar Link	unprocessable
tnon-20230930_lab.xml	Edgar Link	unprocessable
tnon-20230930_def.xml	Edgar Link	unprocessable
tnon-20230930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TNON
Tenon Medical, Inc. Stock $tnon

2023 Q4 Form 10-Q Financial Statement

#000121390023087015 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNON Tenon Medical, Inc. Stock $tnon

2023 Q4 Form 10-Q Financial Statement

#000121390023087015 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNON
Tenon Medical, Inc. Stock $tnon